Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • New and Noteworthy
    • Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Special Collections
    • Recent ADA Position Statements
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • New and Noteworthy
    • Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Special Collections
    • Recent ADA Position Statements
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • Peer Review
Diabetes Care Electronic Pages

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases

  1. Efi Pasmatzi, MD1,
  2. Alexandra Monastirli, MD1,
  3. John Habeos, MD2,
  4. Sophia Georgiou, MD1 and
  5. Dionysios Tsambaos, PHD1
  1. From the 1Department of Dermatology, School of Medicine, University of Patras, Patras, Greece; and the
  2. 2Department of Internal Medicine, Division of Endocrinology, School of Medicine, University of Patras, Patras, Greece
  1. Corresponding author: Efi Pasmatzi, pasmatzi{at}med.upatras.gr.
Diabetes Care 2011 Aug; 34(8): e133-e133. https://doi.org/10.2337/dc11-0804
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Bullous pemphigoid (BP) is an autoimmune disorder characterized by the production of autoantibodies against two antigens (BPAG1 and 2) and can be induced by drugs (1,2). Recently, the development of BP was reported in diabetic patients treated with dipeptidyl peptidase-4 inhibitors (gliptins) plus metformin (3). However, it remains unknown whether gliptins alone or in combination with metformin are responsible for the induction of BP. We report two diabetic patients who developed BP shortly after addition of vildagliptin to their metformin monotherapy.

A 59-year-old woman and a 67-year- old man, both with type 2 diabetes that had been controlled with metformin for 6 and 3 years, respectively, presented with an 1- and 3-month history of pruritic skin lesions, respectively, that developed 2 months after onset of combined therapy with vildagliptin and metformin. Physical examination revealed a diffuse bullous eruption mostly on an erythematous base. Both patients had no history or evidence of autoimmune, neoplastic, or infectious diseases. In both patients, the results of histological and immunofluorescence investigation of skin biopsy were consistent with the diagnosis of BP. Apart from a slight peripheral eosinophilia, all laboratory investigations were negative. Upon admission, the combined treatment was discontinued in both patients. Patient 1 switched to subcutaneous rapid-acting insulin plus insulin glargine and Patient 2 to metformin plus glimepiride. Upon withdrawal of the gliptin plus metformin combination, there was a significant improvement of eruption, particularly in Patient 2. Patient 1 was treated with 0.5 mg/kg/day methylprednisolone on an 8-week tapering-off scheme, whereas Patient 2 received 200 mg/day doxycycline for a period of 4 weeks. Complete remission was achieved 10 and 8 weeks after discontinuation of vildagliptin plus metformin administration, respectively.

One could argue that in our patients, not vildagliptin but its combination with metformin was involved in the pathogenesis of BP, that the occurrence of the latter was coincidental, or that patients with type 2 diabetes are susceptible to the development of BP. These possibilities cannot be definitely ruled out, however, are very unlikely in view of the following facts: 1) Literature is devoid of any metformin-induced cases of BP and of evidence for patients with type 2 diabetes being susceptible to developing BP or capable of producing autoantibodies against BP antigens. Furthermore, no interaction between metformin and vildagliptin is known. 2) There is a striking temporal relationship between vildagliptin addition to long-term metformin monotherapy and the onset of BP. 3) BP improves upon withdrawal of vildagliptin plus metformin combination. 4) BP in Patient 2 went into remission despite further metformin administration. Thus, it seems reasonable to suggest that in our patients, the development of BP was due to vildagliptin alone. However, the observations of Skandalis et al. (3) indicate that induction of BP is a side effect most probably shared by all gliptins and not exclusively related to vildagliptin. In view of the wide use of these compounds in the treatment of type 2 diabetes, it is obvious that further studies are now warranted to validate our observations, definitely evaluate the potential of gliptins to cause BP, and to elucidate the corresponding pathogenetic mechanisms.

Acknowledgments

No potential conflicts of interest relevant to this article were reported.

E.P. wrote the manuscript. A.M. researched data and helped draft the manuscript. J.H. researched data. S.G. researched data. D.T. reviewed and edited the manuscript. All authors have read and approved the submitted manuscript.

  • © 2011 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. Bastuji-Garin S,
    2. Joly P,
    3. Picard-Dahan C,
    4. et al
    . Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 1996;132:272–276
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Fellner M
    . Drug-induced bullous pemphigoid. Clin Dermatol 1993;11:515–520
    OpenUrlCrossRefPubMed
  3. ↵
    Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas I. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 6 April 2011 [Epub ahead of print].
View Abstract
PreviousNext
Back to top
Diabetes Care: 34 (8)

In this Issue

August 2011, 34(8)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
Citation Tools
Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
Efi Pasmatzi, Alexandra Monastirli, John Habeos, Sophia Georgiou, Dionysios Tsambaos
Diabetes Care Aug 2011, 34 (8) e133; DOI: 10.2337/dc11-0804

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
Efi Pasmatzi, Alexandra Monastirli, John Habeos, Sophia Georgiou, Dionysios Tsambaos
Diabetes Care Aug 2011, 34 (8) e133; DOI: 10.2337/dc11-0804
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Diabetes Care Electronic Pages

  • Comment on: Hegde et al. Effect of 3-Month Yoga on Oxidative Stress in Type 2 Diabetes With or Without Complications: A Controlled Clinical Trial. Diabetes Care 2011;34: 2208–2210
  • Successful Use of Omalizumab in an Inadequately Controlled Type 2 Diabetic Patient With Severe Insulin Allergy
  • Response to Comment on: Calleja et al. Insulin Resistance Is Associated With a Poor Response to Intravenous Thrombolysis in Acute Ischemic Stroke. Diabetes Care 2011;34:2413–2417
Show more 3

Online Letters: Observations

  • Tyrosine Kinase Inhibitor Sunitinib Allows Insulin Independence in Long-standing Type 1 Diabetes
  • FGF23 in Type 2 Diabetic Patients: Relationship With Bone Metabolism and Vascular Disease
  • Diabetic Charcot Neuroarthropathy of the Hand: Clinical Course, Diagnosis, and Treatment Options
Show more 3

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • BMJ Open - Diabetes Research & Care
  • Standards of Medical Care in Diabetes
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2018 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.